logo
logo
KMDA stock ticker logo

Kamada Ltd.

NASDAQ•KMDA
CEO: Mr. Amir London
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Listing Date: 2013-05-31
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Contact Information
2 Holzman Street, Science Park PO Box 4081, Rehovot, 7670402, Israel
972-8-940-6472
www.kamada.com
Market Cap
$530.09M
P/E (TTM)
26.5
37.7
Dividend Yield
2.2%
52W High
$9.35
52W Low
$5.54
52W Range
96%
Rank38Top 36.9%
4.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$47.01M+12.63%
4-Quarter Trend

EPS

$0.09+28.57%
4-Quarter Trend

FCF

$6.83M-66.02%
4-Quarter Trend

2024 Annual Earnings Highlights

Key Highlights

Proprietary Revenue Surges 23% Proprietary Products revenue reached $141.4M in 2024, up 23%, driven by strong KEDRAB demand in the U.S. market.
Total Gross Profit Up 26% Total gross profit increased 26% to $69.9M in 2024, reflecting improved sales mix and operational efficiencies achieved.
KEDRAB Distribution Agreement Secured Secured minimum aggregate revenues of approximately $180.0M through 2027 via the fifth amendment to the KEDRAB supply agreement.
Plasma Collection Capacity Expanding Expanded U.S. plasma collection operations with Houston center operational and San Antonio center opening Q1 2025.

Risk Factors

Business Highly Revenue Concentrated Business heavily relies on KEDRAB and CYTOGAM, representing over 55% of gross profitability in 2024.
Dependency on Kedrion Partnership Disruption to the U.S. KEDRAB distribution relationship with Kedrion poses a material adverse effect risk.
Inhaled AAT Trial Results Uncertain Pivotal Phase 3 InnovAATe trial results are uncertain; interim futility analysis scheduled for completion by end of 2025.
Israeli Political Instability Risk Political, economic, and military instability in Israel may adversely affect manufacturing facility operations and supply chains.

Outlook

2025 Revenue Guidance Issued Expect total revenues for fiscal year 2025 in the range of $178M to $182M, representing 12% revenue increase midpoint.
Strategic Growth Pillars Focus Strategy focuses on commercialization, securing new M&A/licensing opportunities in 2025, and expanding plasma collection.
Israel Biosimilar Portfolio Launch Launch two biosimilar products in Israel in 2025, estimating portfolio revenue growth to $15M–$20M within five years.
Manufacturing Transition Planned Plan to transition manufacturing of HEPAGAM B, VARIZIG, and WINRHO SDF to Beit Kama facility over four to five years.

Peer Comparison

Revenue (TTM)

AGL stock ticker logoAGL
$5.93B
-2.1%
EBS stock ticker logoEBS
$742.90M
-28.8%
TCMD stock ticker logoTCMD
$329.52M
+12.5%

Gross Margin (Latest Quarter)

AMRN stock ticker logoAMRN
119.2%
+7.3pp
SMLR stock ticker logoSMLR
91.5%
+0.1pp
XOMA stock ticker logoXOMA
90.6%
-9.4pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
TCMD$676.98M35.49.3%5.8%
SRDX$614.51M-34.8-15.6%19.2%
CGC$555.68M-1.6-52.9%23.1%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
6.4%
Steady Growth
4Q Net Income CAGR
11.6%
Profitability Improving
Cash Flow Stability
75%
Volatile Cash Flow

Deep Research

Next earnings:May 12, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data